Literature DB >> 11445252

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

S De Santi1, M J de Leon, H Rusinek, A Convit, C Y Tarshish, A Roche, W H Tsui, E Kandil, M Boppana, K Daisley, G J Wang, D Schlyer, J Fowler.   

Abstract

We used MRI volume sampling with coregistered and atrophy corrected FDG-PET scans to test three hypotheses: 1) hippocampal formation measures are superior to temporal neocortical measures in the discrimination of normal (NL) and mild cognitive impairment (MCI); 2) neocortical measures are most useful in the separation of Alzheimer disease (AD) from NL or MCI; 3) measures of PET glucose metabolism (MRglu) have greater diagnostic sensitivity than MRI volume. Three groups of age, education, and gender matched NL, MCI, and AD subjects were studied. The results supported the hypotheses: 1) entorhinal cortex MRglu and hippocampal volume were most accurate in classifying NL and MCI; 2) both imaging modalities identified the temporal neocortex as best separating MCI and AD, whereas widespread changes accurately classified NL and AD; 3) In most between group comparisons regional MRglu measures were diagnostically superior to volume measures. These cross-sectional data show that in MCI hippocampal formation changes exist without significant neocortical changes. Neocortical changes best characterize AD. In both MCI and AD, metabolism reductions exceed volume losses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445252     DOI: 10.1016/s0197-4580(01)00230-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  193 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

5.  Medial temporal lobe function and structure in mild cognitive impairment.

Authors:  Bradford C Dickerson; David H Salat; Julianna F Bates; Monika Atiya; Ronald J Killiany; Douglas N Greve; Anders M Dale; Chantal E Stern; Deborah Blacker; Marilyn S Albert; Reisa A Sperling
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

6.  Event-related functional magnetic resonance imaging changes during relational retrieval in normal aging and amnestic mild cognitive impairment.

Authors:  Kelly S Giovanello; Felipe De Brigard; Jaclyn Hennessey Ford; Daniel I Kaufer; James R Burke; Jeffrey N Browndyke; Kathleen A Welsh-Bohmer
Journal:  J Int Neuropsychol Soc       Date:  2012-05-24       Impact factor: 2.892

7.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

8.  Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model.

Authors:  Ahmet Turan Isik; Turgay Celik; Gokhan Ulusoy; Onder Ongoru; Birsen Elibol; Huseyin Doruk; Ergun Bozoglu; Hakan Kayir; Mehmet Refik Mas; Serif Akman
Journal:  Age (Dordr)       Date:  2008-10-08

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 10.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.